The National Cardiovascular Disease Database for Malaysia has been going on, producing good, interesting annual reports (so far, two reports been produced: 2006 for ACS Registry, and 2007 for PCI Registry). Click here for FREE Downloads of the two reports.
I find the information there very useful as I prepare for my talk in 13th International Conference on Emergency Medicine. Powerpoint slides based on the data are also available for free download.
Download the article based on the ACS Registry, published in Medical Journal of Malaysia here.
Here are some facts I have gathered from the Malaysian ACS Registry:
1. The 30-day mortality for the entire STEMI cohort is 11%, as compared to the NSTEMI 8%, Unstable Angina (UA) 4%.
2. When divided into those that received fibrinolytics and those that did not in the cohort of STEMI, those that received fibrinolytics has a 30-day mortality of 9%, and those that did not 16% (almost 50% reduction in mortality).
* A review by the Fibrinolytic Therapy Trialists (FTT) showed that fibrinolysis reduced mortality by 25%.
That shows the importance of getting the patient as early as possible for thrombolysis or PCI when STEMI is diagnosed.
4. As for percutaneous coronary intervention (PCI), most (more than 90%) of all PCI in participating sites for the registry data were elective PCI.
5. More than 50% of the stents used in PCI were the Drug Eluting Stents.
6. Most common location lesion site stented was the left anterior descending artery. It is not surprising given that anterior infarct carries higher risk of streptokinase failure.
PLEASE NOTE: All contents in this blog are copyrighted materials, unless otherwise stated. Even if you encounter materials in this page without a copyright notice, it does not mean that it is not copyrighted (Click here to read TEN BIG myths on copyright explained). This is especially so as most nations are signatories of the Berne Convention on international copyright law (World Intellectual Property Organization). Nevertheless, I have licensed almost all the materials contained here under Creative Commons licenses strictly for educational, non-commercial purposes only. Kindly email me at email@example.com should you want to use any of the materials for commercial purposes. Thank you.